trending Market Intelligence /marketintelligence/en/news-insights/trending/EWHaNAo6LxXPVf16Qc2MPA2 content esgSubNav
In This List

Prometic shareholders approve name change to Liminal BioSciences

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Prometic shareholders approve name change to Liminal BioSciences

Prometic Life Sciences Inc. shareholders approved the company's name change to Liminal BioSciences Inc.

In a special meeting of shareholders, about 87% of votes cast were in favor of the change.

The Canadian biopharmaceutical company's shares are expected to begin trading under the ticker symbol LMNL on or about Oct. 7, subject to final approval by The Toronto Stock Exchange, which already accepted the notice of the proposed change.

The change will take effect when Prometic Life Sciences receives the certificate of amendment under the Canada Business Corporations Act.

Prometic develops therapies to treat patients with rare liver, respiratory and kidney disease.